Northern Trust Corp Acquires 1,172,931 Shares of Haleon plc (NYSE:HLN)

Northern Trust Corp raised its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 27.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,412,542 shares of the company's stock after acquiring an additional 1,172,931 shares during the quarter. Northern Trust Corp owned approximately 0.12% of Haleon worth $51,636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC boosted its stake in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after acquiring an additional 6,175,835 shares during the last quarter. Douglas Lane & Associates LLC lifted its stake in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company's stock valued at $82,274,000 after buying an additional 161,865 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Haleon by 0.8% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company's stock valued at $72,793,000 after buying an additional 58,444 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Haleon by 18.3% during the 4th quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company's stock valued at $57,382,000 after buying an additional 930,701 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Price Performance

NYSE HLN traded down $0.22 on Tuesday, reaching $10.49. The company had a trading volume of 9,875,710 shares, compared to its average volume of 7,827,919. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $47.31 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The firm's 50 day moving average price is $10.21 and its 200 day moving average price is $9.84. Haleon plc has a 12 month low of $8.24 and a 12 month high of $10.85.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, equities analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is an increase from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. Haleon's payout ratio is 58.97%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HLN shares. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays restated an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research note on Friday. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Haleon currently has a consensus rating of "Moderate Buy" and an average target price of $11.25.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.